Skip to content

Inspection Record

Alkem Laboratories Limited — FDA 483 Findings

US FDAInspected 2024-03-27Published 2024-04-09 9 findingsContamination controlLaboratory and QC controlsDeviation, CAPA, and investigationEquipment and facilityProcess validationQuality unit oversight

View the regulator's official source The source document is always the basis for judgement.

Findings

1Contamination control

There wasa failure to handle and store drug product containers at all times in a manner to prevent contamination.

2Laboratory and QC controls

Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.

3Contamination control

Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.

4Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

5Laboratory and QC controls

Appropriate controls governing computer acquired data and/or related systems have not been established to assure that changes and access to computerized software for laboratory control system or other systems is instituted/accessed only by authorized personnel.

6Equipment and facility

Buildings used in the manufacturing, processing, packing, and holding of a drug product are not maintained in a good state of repair.

7Equipment and facility

Equipment and utensils are not cleaned, maintained, and sanitized at appropriate intervals to prevent contamination of the products.

8Process validation

Control procedures are not established which [monitor the output] [validate the performance] of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.

9Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2024-04-09. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Alkem Laboratories Limited findings history — including this company's other documentsAll US FDA findings US FDA documents, 2024 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.